Major Lipids, Apolipoproteins, and Risk of Vascular Disease

被引:0
|
作者
Di Angelantonio, Emanuele
Sarwar, Nadeem
Perry, Philip
Kaptoge, Stephen
Ray, Kausik K.
Thompson, Alexander
Wood, Angela M.
Lewington, Sarah [2 ]
Sattar, Naveed [3 ]
Packard, Chris J. [3 ]
Collins, Rory [2 ]
Thompson, Simon G. [4 ]
Danesh, John [1 ]
机构
[1] Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Emerging Risk Factors Collaborat Coordinating Ctr, Cambridge CB1 8RN, England
[2] Univ Oxford, Oxford, England
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] MRC, Biostat Unit, Cambridge CB2 2BW, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 302卷 / 18期
基金
英国医学研究理事会;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; NONFASTING TRIGLYCERIDES; CARDIOVASCULAR-DISEASE; HDL CHOLESTEROL; ASSOCIATION; CORONARY; STROKE; PARTICIPANTS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified. Objective To assess major lipids and apolipoproteins in vascular risk. Design, Setting, and Participants Individual records were supplied on 302 430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes. Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. Results The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C. Conclusion Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. JAMA. 2009; 302(18): 1993-2000
引用
收藏
页码:1993 / 2000
页数:8
相关论文
共 50 条
  • [1] Apolipoproteins, lipids and risk of cancer
    Borgquist, Signe
    Butt, Talha
    Almgren, Peter
    Shiffman, Dov
    Stocks, Tanja
    Orho-Melander, Marju
    Manjer, Jonas
    Melander, Olle
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (11) : 2648 - 2656
  • [2] Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
    Bajaj, Archna
    Xie, Dawei
    Cedillo-Couvert, Esteban
    Charleston, Jeanne
    Chen, Jing
    Deo, Rajat
    Feldman, Harold, I
    Go, Alan S.
    He, Jiang
    Horwitz, Edward
    Kallem, Radhakrishna
    Rahman, Mahboob
    Weir, Matthew R.
    Anderson, Amanda H.
    Rader, Daniel J.
    Appel, Lawrence J.
    Kusek, John W.
    Lash, James P.
    Rao, Panduranga S.
    Townsend, Raymond R.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (06) : 827 - 836
  • [3] LIPIDS AND APOLIPOPROTEINS IN PATIENTS TREATED WITH MAJOR TRANQUILIZERS
    SASAKI, J
    FUNAKOSHI, M
    ARAKAWA, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (06) : 684 - 687
  • [4] Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study
    Pikkemaat, Miriam
    Woodward, Mark
    Af Geijerstam, Peder
    Harrap, Stephen
    Hamet, Pavel
    Mancia, Giuseppe
    Marre, Michel
    Poulter, Neil
    Chalmers, John
    Harris, Katie
    DIABETES OBESITY & METABOLISM, 2024, 26 (12): : 5669 - 5680
  • [5] Major Lipids, Apolipoproteins, and Alterations of Gut Microbiota
    Yun, Kyung Eun
    Kim, Jimin
    Kim, Mi-hyun
    Park, Eunkyo
    Kim, Hyung-Lae
    Chang, Yoosoo
    Ryu, Seungho
    Kim, Han-Na
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [6] SERUM-LIPIDS AND APOLIPOPROTEINS AS RISK INDICATORS FOR CEREBROVASCULAR-DISEASE
    KOSTNER, GM
    MARTH, E
    PFEIFFER, KH
    CIRCULATION, 1983, 68 (04) : 171 - 171
  • [7] Lipids, lipoproteins, and apolipoproteins and their disease associations
    Ogedegbe, HO
    Brown, DW
    LABORATORY MEDICINE, 2001, 32 (07) : 384 - 389
  • [8] Lipids, apolipoproteins, carbohydrates, and risk of hematological malignancies
    Liu, Qianwei
    Wei, Dang
    Hammar, Niklas
    Yang, Yanping
    Feychting, Maria
    Zhang, Zhe
    Walldius, Goeran
    Smedby, Karin E.
    Fang, Fang
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2025, : 187 - 196
  • [9] STUDIES OF LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS IN MENKES DISEASE
    BLACKETT, PR
    LEE, DM
    DONALDSON, DL
    FESMIRE, JD
    CHAN, WY
    HOLCOMBE, JH
    RENNERT, OM
    PEDIATRIC RESEARCH, 1984, 18 (09) : 864 - 870
  • [10] Diabetic dyslipidemia, apolipoproteins, and vascular risk
    Gupta, Rajeev
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2007, 1 (01) : 49 - 51